Why the study?
Does levosimendan improve outcomes compared to dobutamine in patients with acute, decompensated heart failure?
Does levosimendan improve outcomes compared to dobutamine in patients with acute, decompensated heart failure?
Levosimendan appears to be a safe and effective alternative to dobutamine for treating acute, decompensated heart failure in patients unresponsive to diuretics and vasodilators.
Answers are grounded in this paper and cite their sources.
May support levosimendan over dobutamine in acute decompensated HF; hypothesis-generating and leaves open need for confirmatory RCTs.
OBJECTIVE: To review the literature on a novel calcium sensitizer, levosimendan. DATA SOURCES: Articles were identified through searches of MEDLINE (1966-June 2005), International Pharmaceutical Abstracts (1970-June 2005), and EMBASE (1992-June 2005) using the key words levosimendan, simendan, calcium sensitizer, calcium sensitiser, and congestive heart failure. STUDY SELECTION AND DATA EXTRACTION: Clinical trials and pharmacokinetic studies evaluating the safety and efficacy of levosimendan were selected. DATA SYNTHESIS: Levosimendan 6-24 mug/kg intravenous bolus followed by a 24-hour continuous infusion of 0.05-0.2 microg/kg/min improved cardiac output and reduced pulmonary capillary wedge pressure in a dose-dependent manner. Dose-ranging and randomized clinical trials have demonstrated improvement in symptoms and hemodynamics and short-term survival outcomes in the treatment of acute, decompensated heart failure. Clinical trials evaluating retrospective mortality data and combined endpoints (mortality, rehospitalization) have demonstrated better outcomes with levosimendan compared with dobutamine. The incidence of hypotension with levosimendan is not significantly different than with dobutamine, but there is a dose-related increase in heart rate. CONCLUSIONS: Levosimendan is useful in moderate to severe low-output heart failure in patients who have failed to respond to diuretics and vasodilators. Based on current studies, levosimendan appears to be a safe alternative to dobutamine for treatment of acute, decompensated heart failure. Prospective clinical trials are needed to confirm the effect of levosimendan on long-term survival and its role in heart failure in the setting of myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Earl et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: